Notering av Ultimovacs ASA på Oslo Børs

Søkt notering: 21.05.2019
Vedtatt notert: 24.05.2019
Noteringsdato: 03.06.2019
Ticker: ULTIMO

Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer. The lead product candidate is UV1, a therapeutic cancer vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 may serve as a platform for use in combination with other immunotherapy drugs across multiple cancer types. Ultimovacs is performing a development program with clinical trials in Europe and the USA.

 Aksje- og selskapsdata, meldinger fra selskapet og historikk

Kontakt oss

Linn Cathrin Slettedal